Mesothelioma | Mesothelioma

... Emisphere Reports Results of Study Comparing its Oral Heparin Formulation to Traditional Injectable Heparin Emisphere Reports Results of Study Comparing its Oral Heparin Formulation to Traditional Injectable Heparin Results Show that Heparin Delivered Orally Using Emisphere's eligen(R) Technology is Identical to Heparin Delivered by Injection Based on all Analytical Methods Utilized TARRYTOWN, N.Y., March 31 /PRNewswire-FirstCall/ - Emisphere Technologies, Inc.

(Nasdaq: EMIS) today announced results of a clinical study designed to compare heparin administered in the Company's proprietary oral formulation to heparin administered by the two standard methods of injection.

The purpose of the study was to demonstrate that heparin's molecular configuration when delivered by the oral route using the Emisphere's eligen(R) technology is unaltered as compared to heparin when administered by either the subcutaneous or intravenous routes of administration.

The results show that heparin delivered orally utilizing Emisphere's eligen(R) drug delivery technology, is chemically identical to heparin delivered by injection.

The study was conducted as a result of discussions with the U.S.

Food and Drug Administration ("FDA") regarding potential expedited registration pathways for oral heparin.

Previous studies have repeatedly demonstrated that Emisphere's oral heparin formulation can elevate the key parameters of anticoagulation (aptt, anti-Factor ...

Read more...